CraniUS Therapeutics Honored as 2025 Emerging Life Sciences Company in Maryland

CraniUS Therapeutics Receives Prestigious Award

In a remarkable achievement, CraniUS Therapeutics has been named the '2025 Emerging Life Sciences Company of the Year' by the Maryland Tech Council (MTC). The announcement was made during a gala event that celebrated excellence in technology and life sciences, attended by over 600 industry leaders and innovators. This accolade places CraniUS at the forefront of scientific innovation, recognizing their substantial contributions to advancing intracranial drug delivery.

Founded by the pioneering Dr. Chad Gordon, a renowned expert in Neuroplastic and Reconstructive Surgery, CraniUS is dedicated to addressing significant challenges in neurology. Dr. Gordon, who also serves as the Section Chief and Fellowship Program Director at the prestigious Johns Hopkins School of Medicine, has an impressive track record, having secured 21 patents and conducted successful first-in-human studies related to cranial implants. These endeavors led to the creation of the company’s flagship device, NeuroPASS™, which plays a critical role in their mission.

The award from the MTC underscores CraniUS's groundbreaking work on the NeuroPASS™ platform—an innovative solution designed for the direct delivery of therapeutics to the brain. This technology addresses persistent hurdles in the treatment of brain tumors and various neurological disorders. During the acceptance speech, Dr. Gordon expressed gratitude for the recognition, highlighting the need for transformative neurotherapeutic solutions. He stated, "This milestone reflects not only the dedication of our entire team but also the urgent need for transformative solutions in neurotherapeutics."

Alongside Dr. Gordon, Mike Maglin, the CEO of CraniUS Therapeutics, shared his thoughts on the award, reinforcing the company’s commitment to making significant strides in neurological care. He remarked, "This award is a testament to the meaningful progress we've made and the momentum we've built. We remain committed to redefining how patients with neurological diseases receive life-changing medicines."

The Maryland Tech Council’s Industry Awards Celebration is esteemed for honoring outstanding achievements in Maryland's technology and life sciences sectors. CraniUS Therapeutics was chosen among numerous contenders owing to its rapid growth, exceptional leadership, and innovative device platform, which leverages patented neurotechnology aimed at revolutionizing treatment methodologies for conditions like neurodegenerative diseases, movement disorders, and aggressive brain cancers.

Located in Baltimore, Maryland, CraniUS Therapeutics collaborates with top-tier experts in neurosurgery, drug delivery, and medical device engineering. The company strives to reshape patients’ lives with neurological conditions by developing a fully implantable platform that bypasses the blood-brain barrier, enabling long-term, programmable drug delivery. The NeuroPASS™ device symbolizes a shift in therapeutic applications for sustained medical impact.

In conclusion, CraniUS Therapeutics not only represents a beacon of hope for patients with debilitating neurological conditions but also embodies the innovative spirit that Maryland Tech Council seeks to celebrate. As they continue to forge partnerships and advance their technology, the future looks promising for this award-winning company poised to transform the narratives of neurological care worldwide.

For more information, please contact:
Elizabeth A. Dale, EdD
Executive Advisor, CraniUS Therapeutics
Email: [email protected]
Phone: 215-620-4482